




FIG. 1A




FIG. 1B




FIG. 1C




FIG. 1D




FIG. 1E




FIG. 1F

FIG. 2A




FIG. 2B





FIG. 2C



3/11

FIG. 3A




FIG. 3B




FIG. 3C





FIG. 3D






FIG. 4




FIG. 5




FIG. 6




FIG. 7






FIG. 8



Comparison of the hydrophilicity of MB-3a, DS-8201a, and trastuzumab


FIG. 9

11/11



The antigen binding affinity of MB-3a, DS-8201a, and trastuzumab

FIG. 10



Comparison of the bystander effect of MB-3a, DS-8201a, and T-DM1

FIG. 11